Humacyte (HUMA) director Kathleen Sebelius purchases 56,818 shares at $0.88

Rhea-AI Filing Summary

Humacyte, Inc. director Kathleen Sebelius reported an open-market purchase of 56,818 shares of Humacyte common stock at a price of $0.88 per share on May 19, 2026. Following this transaction, she directly holds a total of 148,025 Humacyte common shares.

Insider Trade Summary

Net Buyer: 56,818 shares ($50,000)

Net Buy 1 txn

Insider Sebelius Kathleen

Role null

Bought 56,818 shs ($50K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	56,818	$0.88	$50K

Holdings After Transaction: Common Stock — 148,025 shares (Direct, null)

Footnotes (1)

Key Figures

Shares purchased: 56,818 shares Purchase price: $0.88 per share Shares owned after: 148,025 shares +1 more

4 metrics

Shares purchased 56,818 shares Open-market buy on May 19, 2026

Purchase price $0.88 per share Price paid for Humacyte common stock

Shares owned after 148,025 shares Direct holdings following the transaction

Net buy shares 56,818 shares Net buy direction from transaction summary

Key Terms

open-market purchase, Common Stock, Form 4, insider

4 terms

open-market purchase financial

"reported an open-market purchase of 56,818 shares of Humacyte common stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"purchase of 56,818 shares of Humacyte common stock at a price of $0.88"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"according to the filed Form 4 data"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

insider regulatory

"The insider is Kathleen Sebelius, a director of Humacyte, Inc."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sebelius Kathleen

(Last) (First) (Middle)

2525 EAST NORTH CAROLINA HIGHWAY 54

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		P		56,818	A	$0.88	148,025	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Kathleen Sebelius by Dale A. Sander as Attorney-in-Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Humacyte (HUMA) director Kathleen Sebelius buy?

Kathleen Sebelius bought 56,818 shares of Humacyte common stock. The open-market purchase was made at a price of $0.88 per share, increasing her direct ownership to a total of 148,025 Humacyte common shares after the transaction.

At what price did Kathleen Sebelius buy Humacyte (HUMA) shares?

She purchased Humacyte common stock at $0.88 per share in an open-market transaction. The filing shows a single trade of 56,818 shares on May 19, 2026, resulting in direct ownership of 148,025 shares after the purchase was completed.

How many Humacyte (HUMA) shares does Kathleen Sebelius now own?

After the reported transaction, Kathleen Sebelius directly owns 148,025 Humacyte common shares. This reflects the addition of 56,818 shares purchased on May 19, 2026, at $0.88 per share, as disclosed in the Form 4 insider trading report.

Was the Humacyte (HUMA) insider transaction an open-market purchase?

Yes, the transaction was an open-market purchase of Humacyte common stock. The Form 4 identifies the code as "P," meaning a purchase, and describes it as an open-market transaction at $0.88 per share for 56,818 shares on May 19, 2026.

Who is the insider involved in the latest Humacyte (HUMA) Form 4?

The insider is Kathleen Sebelius, a director of Humacyte, Inc. She reported buying 56,818 shares of the company’s common stock at $0.88 per share, bringing her direct holdings to 148,025 shares according to the filed Form 4 data.